H. Michael Shepard

Who is H. Michael Shepard?

H. Michael Shepard is an American cancer researcher.

He holds a bachelor's degree from the University of California, Davis. He received a Ph.D. from the Indiana University. Dr. Shepard was a Damon Runyon Cancer Research Foundation Fellow at Indiana University. He, is a founder, president and CSO of Receptor BioLogix, a California-based biopharmaceutical company focused on developing a newly discovered class of protein therapeutics called Intron Fusion Proteins to treat cancer, autoimmune, metabolic and other diseases. Formerly, he was chief scientific officer and vice president of research at Canji, Inc., where he developed the application of the p53 gene product for cancer treatment. While at Genentech, he led the discovery and development of the breast cancer drug, Trastuzumab.

Dr. Shepard shared the 2006 Alpert Prize for his contribution to the development of the breast cancer therapy Herceptin, the first target-directed cancer treatment for solid tumors.

Dr. Shepard holds over 25 US patents.